CARTI Marks First Clinical Use of RenovoCath® for Sarcoma Patient Treatment
LITTLE ROCK, Ark. (Aug. 6, 2026) – CARTI recently marked the first commercial clinical use of RenovoCath®, a patented, FDA-cleared device that enables local chemotherapy delivery near a tumor site rather than traditional systemic intravenous administration. Initial treatment using RenovoCath® for a patient with sarcoma—a cancer that starts in the soft tissues or bones—began in … Continued